Tacrolimus-based triple-drug immunosuppression minimizes serum lipid elevations in pediatric cardiac transplant recipients

Journal of Heart and Lung Transplantation

Volumn 18, Issue 7, 1999, Pages 707-713

  Penson, Matthew G ^a   Winter, William E ^a,b   Fricker, F Jay ^a   Harker, Kelli ^b   Kahler, Deborah A ^b   Kubilis, Paul S ^a   Schowengerdt, Kenneth O ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHOLESTEROL; CORTICOSTEROID; CYCLOSPORIN; LIPOPROTEIN; MYCOPHENOLIC ACID; PREDNISONE; TACROLIMUS; TRIACYLGLYCEROL;

ADOLESCENT; ARTERY DISEASE; ARTICLE; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ANALYSIS OF VARIANCE; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIPIDS; MALE; POSTOPERATIVE CARE; STATISTICS, NONPARAMETRIC; TACROLIMUS;

EID: 0032779968     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(99)00023-6     Document Type: Article

References (20)

1. Boucek M.M., Novick R.J., Bennett L.E., Fiol B., Keck B.M., Hosenpud J.D. The Registry of the International Society for Heart and Lung Transplantation: Second Official Pediatric Report-1998. J Heart Lung Transplant. 17:1998;1141-1160.
2. Addonizio L.J., Hsu D.T., Douglas J.F., Kichuk M.R., Michler R.E., Quaegebeur J.M., et al. Decreasing incidence of coronary disease in pediatric cardiac transplant recipients using increased immunosuppression. Circulation. 88:1993;11224-11229.
3. Hess M.L., Hastillo A., Mohanakumar T., Cowley M.J., Vetrovac G., Szentpetery S., et al. Accelerated atherosclerosis in cardiac transplantation: role of cytotoxic B-cell antibodies and hyperlipidemia. Circulation. 68:1983;1194-2101.
4. Eich D., Thompson J.A., Ko D.J., Hastillo A., Lower R., Katz S., et al. Hypercholesterolemia in long-term survivors of heart transplantation: an early marker of accelerated coronary artery disease. J Heart Lung Transplant. 10:1991;45-49.
5. Alonso D.R., Starek P.K., Minick C.R. Studies on the pathogenesis of atheroarteriosclerosis induced in rabbit cardiac allografts by the synergy of graft rejection and hypercholesterolemia. Am J Pathol. 87:1977;415-442.
6. Ballantyne C.M., Podet E.J., Patsch W.P., Harati Y., Appel V., Gotto-AM J., et al. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA. 262:1989;53-56.
7. Chancerelle Y., de Lorgeril M., Viret R., Chiron B., Dureau G., Renaud S., et al. Increased lipid peroxidation in cyclosporine-treated heart transplant recipients. Am J Cardiol. 68:1991;813-816.
8. Keogh A., Simons L., Spratt P., Esmore D., Chang V., Hickie J., et al. Hyperlipidemia after heart transplantation. J Heart Transplant. 7:1988;171-175.
9. Taylor D.O., Thompson J.A., Hastillo A., Barnhart G., Rider S., Lower R.R., et al. Hyperlipidemia after clinical heart transplantation. J Heart Transplant. 8:1989;209-213.
10. Becker D.M., Chamberlain B., Swank R., Hegewald M.G., Girardet R., Baughman K.L., et al. Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. Am J Med. 85:1988;632-638.
11. Uzark K., Crowley D., Callow L., Bove E. Hypercholesterolemia after cardiac transplantation in children. Am J Cardiol. 66:1990;1385-1387.
12. Ballantyne C.M., el Masri B., Morrisett J.D., Torre A.G. Pathophysiology and treatment of lipid perturbation after cardiac transplantation. Curr Opin Cardiol. 12:1997;153-160.
13. Stamler J.S., Vaughan D.E., Rudd M.A., Mudge G.H., Kirshenbaum J., Young P., et al. Frequency of hypercholesterolemia after cardiac transplantation. Am J Cardiol. 62:1988;1268-1272.
14. Loss M., Winkler M., Schneider A., Brinkmann C., Manns M., Ringe B., et al. Influence of long-term cyclosporine or FK 506 therapy on glucose and lipid metabolism in stable liver graft recipients. Transplant Proc. 27:1995;1136-1139.
15. Farmer J.A., Ballantyne C.M., Frazier O.H., Radovancevic B., Payton R.C., Patsch W., et al. Lipoprotein(a) and apolipoprotein changes after cardiac transplantation. J Am Coll Cardiol. 18:1991;926-930.
16. Kasiske B.L. The effects of immunosuppressive agents on plasma lipoproteins after organ transplantation [editorial comment]. J Lab Clin Med. 124:1994;318-319.
17. Armitage J.M., Fricker F.J., Del N.P., Cipriani L., Starzl T.E. The clinical trial of FK 506 as primary and rescue immunosuppression in pediatric cardiac transplantation. Transplant Proc. 23:1991;3058-3060.
18. Swenson J.M., Fricker F.J., Armitage J.M. Immunosuppression switch in pediatric heart transplant recipients: cyclosporine to FK 506. J Am Coll Cardiol. 25:1995;1183-1188.
19. Billingham M.E., Cary N.R.B., et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. J Heart Transplant. 9:1990;587-593.
20. Katznelson S., Wang X.M., Chia D., Ozawa M., Zhong H.P., Hirata M., et al. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro. J Heart Lung Transplant. 17:1998;335-340.